fluoropyrimidine + bevacizumab + atezolizumab

A combination therapy of **fluoropyrimidine** (e.g., 5-fluorouracil or capecitabine), **bevacizumab**, and **atezolizumab**, considered for use in the treatment of certain advanced solid tumors. Fluoropyrimidines are antimetabolite chemotherapeutic agents that inhibit DNA synthesis. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. Atezolizumab is a monoclonal antibody that blocks programmed death-ligand 1 (PD-L1) to enhance antitumor immune responses. This combination leverages cytotoxic chemotherapy, anti-angiogenic and immune checkpoint blockade mechanisms, and may be under clinical development primarily for various cancers, including metastatic colorectal cancer and possibly hepatocellular carcinoma based on regimen similarity, but this specific triple combination is not an approved regimen for any indication as of the current data.